News

Hims & Hers (HIMS) Rallies 11.76% as CEO Not Backing Down After Novo Nordisk Spat
Hims & Hers rebounded by 11.76 percent on Thursday to close at $46.28 apiece amid reaffirmations to continue offering cheaper ...
Becker's Hospital Review2h
Novo Nordisk enters partnership to expand Wegovy access
Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...
Novo Nordisk Just Announced WeightWatchers Will Sell Wegovy
Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...
Hims & Hers Sued Over Wegovy Maker’s Exit, Record Stock Selloff
Hims & Hers Health Inc. investors have sued the telehealth provider days after Novo Nordisk A/S announced it was ending the ...
Novo Nordisk ends collaboration with Hims & Hers for discounted weight loss meds
Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...
Long Island experts weigh in after Novo Nordisk ends deal with Hims & Hers over weight loss meds
Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...
Forbes3d
HIMS Stock To $25?
The collaboration between HIMS and Novo Nordisk, which began in April 2025, was supposed to be a game-changer for the telehealth company. The partnership promised direct access to Wegovy, Novo ...